Conditions: Hepatocellular Carcinoma
Keywords: Hepatocellular carcinoma
Allocation: NON_RANDOMIZED | Intervention model: FACTORIAL
Enrollment: 23
Healthy volunteers: no

Brief summary:
The purpose of this study is:

Phase1: To evaluate the safety and determine the recommended dose (RD) Phase2: To evaluate the efficacy

Detailed description:

Arms:
arm 1: Phase1 step arm 2: Phase2 step

Interventions: intervention 1: OPB-31121 intervention 2: OPB-31121 phase2
Intervention descriptions: intervention 1: Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month) intervention 2: Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)

Protocol document: